To verify whether the combination therapy required immune cell migration from tumor-draining lymph nodes or whether immune cells in the circulation were sufficient to elicit an antitumoral immune response, we evaluated the antitumoral effect of combination therapy in mice injected with FTY720, a sphingosine-1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes (fig. Here, S1PR1 is linked to neoplasm.